Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.35 |
| ▸ | FASN | P49327 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313747 | 0.88 | FLT3 (0.39) | EGLN2CSNK2A2CSNK2A1MEN1KMT2A | |
| SCHEMBL2356690 | 0.87 | KDM4E (0.37) | PIK3CAMTORPRKDCEGLN2MEN1 | |
| SCHEMBL3314986 | 0.85 | TYK2 (0.37) | CSNK2A2CSNK2A1TYK2 | |
| SCHEMBL2359655 | 0.82 | TYK2 (0.46) | PIK3CAMTORPRKDCCSNK2A2CSNK2A1 | |
| SCHEMBL13641674 | 0.81 | CSNK2A2 (0.39) | PIK3CAMTORPRKDCEGLN2CSNK2A2 | |
| SCHEMBL2309711 | 0.81 | CSNK2A2 (0.40) | PRKDCCSNK2A2CSNK2A1KMT2AL3MBTL1 | |
| SCHEMBL3309971 | 0.80 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1TYK2 | |
| SCHEMBL17849715 | 0.80 | TYK2 (0.46) | PIK3CAMTORPRKDCCSNK2A2CSNK2A1 | |
| SCHEMBL3318796 | 0.79 | LRRK2 (0.37) | CSNK2A2CSNK2A1KMT2AL3MBTL1TYK2 | |
| SCHEMBL12012939 | 0.78 | EGFR (0.41) | EGLN2CSNK2A2CSNK2A1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | PIK3CA 106/4885MTOR 183/4885PRKDC 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.